DUBLIN--(BUSINESS WIRE)--The "Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Glucagon Like Peptide 2 Receptor (GLP2R) - Pipeline Review, H2 2017, outlays comprehensive information on the Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Glucagon Like Peptide 2 Receptor (GLP2R) targeted therapeutics development with respective active and dormant or discontinued projects.
Glucagon Like Peptide 2 Receptor (GLP2R) pipeline Target constitutes close to 8 molecules. Out of which approximately 8 molecules are developed by Companies. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 5 respectively. Report covers products from therapy areas Gastrointestinal, Metabolic Disorders and Toxicology which include indications Short Bowel Syndrome, Chemotherapy Effects, Diabetes, Diarrhea, Gastrointestinal Mucositis, Obesity and Type 2 Diabetes.
Key Topics Covered:
- Introduction
- Glucagon Like Peptide 2 Receptor (GLP2R) - Overview
- Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Development
- Products under Development by Stage of Development
- Products under Development by Therapy Area
- Products under Development by Indication
- Products under Development by Companies
- Glucagon Like Peptide 2 Receptor (GLP2R) - Therapeutics Assessment
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Glucagon Like Peptide 2 Receptor (GLP2R) - Companies Involved in Therapeutics Development
- Hanmi Pharmaceuticals Co Ltd
- Naia Ltd
- Shire Plc
- Tasly Pharmaceutical Group Co Ltd
- Zealand Pharma AS
For more information about this report visit https://www.researchandmarkets.com/research/th6shf/glucagon_like
